OneMedPlace (OMP) is a New York based healthcare research and media company that manages a business development platform to help emerging healthcare and life sciences companies maximize their potential. OMP offers an innovative and powerful suite of services to globally connect investors and strategic partners to the companies shaping the future of health and medicine. OMP provides to strategic and financial investors efficient access to information about high potential opportunities around the world the thorough an integrated set of tools.
RegMed Daily, Mid-Day, 11/28/11, stocks rally with optimism for the EU
The 6 W’s: Who, what, where, when, why and what of it …
Stocks rallied Monday as EU leaders moved toward a plan to join euro-zone members in a fiscal union and on evidence US holiday sales got off to a record start. Sorry, late in delivering the Mid-Day …. Family funeral …
Without becoming a kill-joy; the RegMed is in the right business for the future, but, at the moment … it is a survival business. The stock market is beginning to hint of harder times … that I see ahead. The rally … seems to be short-covering phenomena …but, I am nibbling at various companies who are re-showing signs of life from the past months of EU debt and US political contagion …
Still hoping for … any chance of a RegMed “black Friday or buying Monday … optimism … for the next month?
Mid-Day: The NASDAQ is UP +84.14 (+3.45%) to 225.65. The Dow is UP +290.86 (+2.59%) to 11,522.64.
Mid-Day Movers: Aastrom (ASTM), Athersys (ATHX), BioMimetic (BMTI), BioTime (AMEX: BTX), Cytori (CYTX), Dendreon (DNDN), Fibrocell (OTC BB: FCSC), ImmunoCellular (OTC BB: IMUC), Geron (GERN), Osiris (OSIR), Pluristem (PSTI), Neuralstem (AMEX: CUR), ThermoGenesis (KOOL)
What’s new in the regenerative medicine/stem cell market …
ReNeuron (RENE.LON) provided an update on progress with the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this P1 safety study, ReNeuron’s ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischemic stroke, the most common form of the condition. http://www.reneuron.com/news/257
Register here to be notified of future One Med Place articles.
